However, this primarily reflects a lack of systematic investigation rather than confirmed safety
Outcome: Following a collaborative discussion and education on Zepbounds risks in her situation, her care team helped her develop a balanced plan that addressed both her ED recovery and overall health
Not at first, but they eventually relented
Dawkins and Pratley note that while studies show people with obesity and type 2 diabetes experience significant weight loss on a GLP-1 agonist or dual agonist, people with type 2 diabetes experience slightly less weight loss compared with those with overweight and obesity without type 2 diabetes.1-3 Counseling Tips for RDs Despite the success of these classes of weight management medications, patients can receive anywhere from a little to a lot of information on how to optimize their use since a wide variety of clinicians, from primary care providers to obesity medicine experts, prescribe them
[DOI] [PMC free article] [PubMed] [Google Scholar] 77.Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y, et al
